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Pattern recognition receptors (PRRs) in innate immune cells play a pivotal role in 
the first line of host defense system. PRRs recognize pathogen-associated molecu-
lar patterns (PAMPs) or danger-associated molecular patterns (DAMPs) to initiate 
and regulate innate and adaptive immune responses. PRRs include Toll-like recep-
tors (TLRs), RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs), which 
have their own features in ligand recognition and cellular location. Activated PRRs 
deliver signals to adaptor molecules (MyD88, TRIF, MAL/TIRAP, TRAM, IPS-1) 
which act as important messengers to activate downstream kinases (IKK complex, 
MAPKs, TBK1, RIP-1) and transcription factors (NF-κB, AP-1, IRF3), which 
produce effecter molecules including cytokines, chemokines, inflammatory en-
zymes, and type I interferones. Since excessive PRR activation is closely linked to 
the development of chronic inflammatory diseases, the role of intrinsic and extrin-
sic regulators in the prevention of over- or unnecessary activation of PRRs has 
been widely studied. Intracellular regulators include MyD88s, SOCS1, TOLLIP, 
A20, and CYLD. Extrinsic regulators have also been identified with their molecu-
lar targets in PRR signaling pathways. TLR dimerization has been suggested as an 
inhibitory target for small molecules such as curcumin, cinnamaldehyde, and sul-
foraphane. TBK1 kinase can be a target for certain flavonoids such as EGCG, 
luteolin, quercetin, chrysin, and eriodictyol to regulate TRIF-dependent TLR path-
ways. This review focuses on the features of PRR signaling pathways and the ther-
apeutic targets of intrinsic and extrinsic regulators in order to provide beneficial 
strategies for controlling the activity of PRRs and the related inflammatory diseas-
es and immune disorders.
Key Words:    Pattern recognition receptor, toll-like receptor, dimerization, TBK1, 
therapeutic target
INTRODUCTION
Innate and adaptive immunity is required to eliminate pathogens as host defense 
system. Pattern recognition receptors (PRRs), which are germ-line encoded recep-
tors, play a critical role in initiating and regulating innate and adaptive immune re-
sponses by recognizing pathogen-associated molecular patterns (PAMPs) or danger-
associated molecular patterns (DAMPs).1-3 PRRs are quite ubiquitously expressed in 
a variety of cells including monocytes, dendritic cells, neutrophils, and epithelial Eunshil Jeong and Joo Young Lee
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rheumatoid arthritis, asthma, and cancer.9-11 In this report, we 
intend to provide a review of what TLRs, RLRs, NODs, and 
their stimulators or inhibitors are, and show how the intracel-
lular signaling pathways are composed (Summary is depict-
ed in Fig. 1). This information contributes to the develop-
ment of therapeutic intervention strategies for chronic 
inflammatory diseases and immune disorders, through the 
manipulation of PRR activation in a beneficial way.
PATTERN RECOGNITION RECEPTORS
Toll-like receptors
Toll protein, which plays an important role in antifungal de-
fense, was first identified in Drosophila melanogaster 
(fruit-fly).12 Subsequently, the human homologue of Toll 
protein was discovered, and this analogue is referred to as 
the Toll-like receptor.13 So far, at least thirteen members of 
the TLR family have been identified and characterized in 
the mammalian system. TLR1 to TLR9 are conserved in 
both humans and mice. TLR10 is expressed in human, 
cells. The best studied and characterized PRRs are Toll-like 
receptors (TLRs).4,5 TLRs are a family of type I transmem-
brane receptors with an extracellular domain that contains 
leucine-rich-repeat motifs, a transmembrane domain, and a 
conserved cytoplasmic domain known as the toll/interleu-
kin-1 receptor homology domain.6 Another family of PRRs 
is the RIG-I-like receptors (RLRs), which include retinoic 
acid-inducible gene I (RIG-I), melanoma differentiation-as-
sociated gene-5 (MDA-5), and laboratory of genetics and 
physiology 2 (LGP2).7  RLRs are located in the cytoplasm 
and recognize RNA species that are generated by invading 
viruses producing type I IFNs and cytokines.8 The nucleo-
tide binding and oligomerization domain (NOD)-like re-
ceptors (NLRs) are also cytoplasmic PRRs. NOD1 and 
NOD2 belong to the NLR family, and recognize bacterial 
components in order to protect the host from bacterial in-
fection. 
It is now well established that dysregulation of TLRs re-
sults in an increase of uncontrolled inflammation and meta-
bolic syndromes, which contributes to the development and 
progression of chronic diseases, such as atherosclerosis, 
Fig. 1. Intracellular signaling pathways of pattern-recognition receptors.  TLRs are mostly present on the membrane. RLRs and NLRs are located in the cyto-
sol. TLRs send signal through Mal/TIRAP and MyD88 or TRAM/TRIF to IRAK/TRAF6 to activate downstream kinases. RLRs use IPS-1 and TRAF3 as adaptor 
molecules and NLRs transmit activation signals through TRAF6. The signals from TLRs, RLRs, and NLRs are delivered to kinases such as MAPKs, IKKs, 
TBK1, RIP-1, and RICK to activate transcription factor, AP-1, NF-κB, and IRF. Transcription factors bind to specific DNA sequences and produce effecter 
molecules such as cytokines, inflammatory enzymes, chemokines, and type I interferons (IFNs). 
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zymosan) from Saccharamysec cerevisiae.39,40 TLR2 di-
merizes with either TLR1 or TLR6. A study of macrophages 
from TLR1- or TLR6-deficient mice revealed that triacyl li-
popeptide, from Gram-negative bacteria, is the ligand for 
the TLR1/TLR2 complex, and that diacyl lipopeptide, from 
mycoplasma, is the ligand for the TLR2/TLR6 complex.41,42 
In addition, TLR2 forms a complex with non-TLR mole-
cules such as CD36 and dectin-1. CD36, a member of the 
scavenger receptor type B family, has a role as a co-receptor 
for diacylglyceride recognition by the TLR2/TLR6 com-
plex.43 Dectin-1, a C-type lectin receptor, recognizes 
β-glucan from fungal cell wall components, together with 
TLR2 triggering inflammatory responses.44 TLR2 is also 
activated by non-microbial molecules including HSP70 and 
HSP gp96,24,25 hyaluronan,45 and saturated fatty acids.46 In 
addition, TLR2 recognizes carboxyalkylpyrroles which are 
the end products of lipid oxidation.47 The wide responsive-
ness of TLR2 and TLR4 to danger signals, such as sub-
stances released from tissue injury and environmental toxi-
cants, reinforces the theory that TLRs are strongly implicated 
in the development of chronic inflammatory diseases.
TLR5 recognizes flagellin, which is a monomeric con-
stituent of bacterial flagella and an important structural pro-
tein for motile bacteria.48 TLR5 is mainly expressed on the 
luminar surface of epithelial cells in the mucosal tissues 
and respiratory tract.49,50 
TLR11 recognizes profilins from the protozoan parasite 
Toxoplasma gondii51 and uropathogenic E. Coli.52 TLR11 is 
expressed on epithelial cells in the mouse bladder. TLR11-
deficient mice have displayed an increased susceptibility to 
uropathogenic bacteria.52
TLR3, TLR7, TLR8, and TLR9 sense oligonucleotides 
derived from microbes and host cells. TLR3 recognizes 
double-stranded RNA (dsRNA) from the West Nile virus,53 
RSV,54 and encephalomycarditis virus (EMCV)55; recogni-
tion results in the synthesis of type I interferons, such as 
IFNα and IFNβ which are important aspects of the antiviral 
response.56 TLR3 is expressed in myeloid dendritic cells, 
macrophages, B cells and NK cells; but not in plasmacytoid 
dendritic cells (pDCs).57 TLR7 and TLR8 detect viral and 
non-viral single-stranded RNA (ssRNA), and activate IRF3 
and IRF7, leading to production of interferons and cyto-
kines58,59; they also recognize imiquimod and its deriva-
tives. TLR7 is highly expressed in pDCs, but TLR8 is 
mainly present in myeloid dendritic cells and macrophages. 
TLR9 recognizes DNA from the murine cytomegalovirus 
(MCMV)60,61 and Herpes simplex virus 1/2 (HSV1/
while TLR11 to TLR13 are present in mice.14 A study with 
mice deficient of TLRs 1-9, identified each TLR ligand, 
leaving the ligands for TLR10, TLR12, and TLR13 un-
known. TLRs are expressed mainly in various immune 
cells, including monocytes, macrophages, dendritic cells 
and B cells; however, they are also present in non-immune 
cells, such as epithelial cells, endothelial cells, and fibro-
blasts. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 are 
expressed on the cell surface; TLR3, TLR7, TLR8, and 
TLR9 are expressed in intracellular vesicles such as endo-
somes, lysosomes, and the endoplasmic reticulum.15 Epi-
thelial TLR4 is expressed in phagosomes with a unique cel-
lular expression profile. 
Of the thirteen TLRs, TLR4 was characterized first.13 
TLR4 recognizes lipopolysaccharide (LPS) in the outer 
membrane of Gram-negative bacteria, with the assistance of 
co-receptors such as CD14 and MD2.16,17 LPS binds first to 
LPS binding protein (LBP) and membrane-bound GPI 
(glycosylphosphatidylinositol)-anchored CD14, and is then 
transferred to the TLR4 and MD2 (myeloid differentiation 
proten-2) complexes.18,19 In the MD2 complex, LPS binds to 
a large hydrophobic pocket, through non-covalent interac-
tions such as hydrogen bonding and hydrophobic and hydro-
philic interactions, which results in the dimerization of the 
two TLR4/MD2 complexes. In addition, TLR4 recognizes 
mannan from Cadida albicans, glycoinositolphospholipids 
from Trypanosoma,20 and the envelope proteins from mouse 
mammary tumor virus (MMTV) and respiratory syncytial 
virus (RSV).21,22 TLR4 is also activated by endogenous mol-
ecules, including heat-shock proteins (HSP60, HSP70, and 
HSP gp96),23-25 fibrinogen,26 oligosaccharides of hyaluronic 
acid,27 extracellular domain A of fibronectin,28 heparan sul-
fate,29 myeloid-related proteins (Mrp8 and Mrp14),30 oxi-
dized LDL,31 saturated fatty acid32 and amyloid-β.33 Further-
more, human TLR4 senses chemical elements such as nickel 
(Ni2+), conferring immunostimulatory activity to Ni2+.34 Non-
conserved histidine residues in human TLR4 provide binding 
pockets for nickel and trigger an immune response and con-
tact hypersensitivity. 
TLR2 recognizes a variety of PAMPs derived from mi-
crobial organisms, including bacteria, fungi, virus, yeasts, 
and parasites.14 TLR2 detects peptidoglycan, lipoprotein, 
and lipoteichoic acid from Gram-positive bacteria, lipoara-
binomannan from mycobacteria,35 glycosylphosphatidylino-
sitol from Trypanosoma cruzi,36 a phenol-soluble modulin 
from Staphylococcus epidermises,37 hemagglutinin protein 
from the measles virus,38 and polysaccharides (known as Eunshil Jeong and Joo Young Lee
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recognition. The C-terminal domain (CTD) was identified 
as the RNA recognition domain of RIG-I. Structural analy-
sis revealed that CTD forms a cleft-like surface, with posi-
tively charged amino acids that specifically interact with A-
form dsRNA.34 However, it remains to be understood how 
CTD specifically recognizes the 5’-triphosphate group in 
viral dsRNA. The recognition of an RNA ligand by CTD, in-
duces a conformational change in RIG-I, which allows the 
N-terminal CARD to interact with the mitochondrial adaptor 
molecule IPS-1.77 The formation of a RIG-I/IPS-1 complex 
on the mitochondria triggers the assembly of downstream 
proteins to initiate signal transduction. TRAF3/6, caspase 
8/10, RIP1, and Fas-associated death domain (FADD) have 
been demonstrated to be involved in RIG-I signaling.79 
MDA5 is responsible for the detection of Picornaviridae, 
including the Encephalomyocarditis virus and Mengo vi-
rus.80 Since Picornaviridae is known to generate long dou-
ble-stranded replication intermediates in infected cells,81 the 
double-stranded RNA structure has been predicted to be a 
ligand for MDA5. A relatively long poly I:C (>1 kb) is se-
lectively recognized by MDA5, whereas a shorter poly I:C 
generated by enzyme digestion (<1 kb) is detected by RIG-
I. Therefore, the dsRNAs appearing in virus-infected cells 
are recognized differentially by RIG-I and MDA5 depend-
ing on their length. Structural analysis of MDA5 CTD in 
solution and crystal has indicated that its global fold is simi-
lar to that of RIG-I CTD, suggesting that it plays a role in 
the recognition of dsRNA.82 However, the concave surface 
of MDA5 CTD adopts a relatively open structure, suggest-
ing that access by dsRNA may be difficult. The affinity be-
tween MDA5 CTD and dsRNA was so low that recognition 
of dsRNA by MDA5 is likely to require additional adaptor 
molecules.
NOD-like receptors 
NOD-like receptors (NLRs) like RLRs, recognize intracel-
lular PAMPs.83 NLRs include NOD1 and NOD2, which are 
differentiated by their ligand specificity. A ligand of NOD1 
is dipeptide γ-D-glutamyl-meso-diaminopimelic acid (iE-
DAP),84 which is derived from most Gram-negative and cer-
tain Gram-positive bacteria. NOD2 recognizes muramyl di-
peptide (MDP), which is a component of peptidoglycan.85,86 
When NOD1 and NOD2 are activated by ligands, NF-κB, 
MAP kinase p38, ERK, and JNK are activated through an 
signaling cascade, resulting in the production of cytokines.87,88 
In order to activate MAP kinase, CARD9, a CARD-contain-
ing adaptor protein, acts as a downstream component of 
HSV2),62,63 and unmethylated CpG motifs from bacteria 
and viruses, which induce inflammatory cytokines and type 
I IFNs.64 CpG DNA is a potent inducer of Type I IFNs in 
plasmacytoid dendritic cells, and is utilized as a vaccine ad-
juvant against viral infection.65 
   
RIG-I-like receptors 
RLRs are the primary sensor molecules for detecting viral 
RNA in the cytoplasm.7,66 Three RLRs have been identi-
fied: RIG-I (also known as DDX58), MDA5 (also known 
as Helicard), and LGP2. RIG-I and MDA5 contain both a 
caspase recruitment domain (CARD) and a RNA helicase 
domain.67
Activation of RIG-I generates type I IFNs in response to 
both viral infection and synthetic RNA introduced into the 
cytoplasm.68 RIG-I is essential for the recognition of ss-
RNA viruses, such as paramyxoviruses, the influenza virus, 
and VSV (vesicular stomatitis virus). Therefore, RIG-I defi-
ciency disrupts immune responses to specific ssRNA virus-
es resulting in the increased susceptibility of mice exposed 
to RNA viruses.69 Host cells contain an abundance of their 
own RNA, but host RNA, unlike viral RNA, fails to be rec-
ognized by RIG-I. RIG-I binds to the 5’-triphosphate moi-
ety, the signature of which is exposed in the process of viral 
entry or replication. This specificity explains the strict dis-
crimination between self and non-self RNA by RIG-I; be-
cause most endogenous RNAs lose their 5’-triphosphate 
group during maturation, and thereby escape detection by 
RIG-I. Short dsRNA (<1 kb) also behaves as a RIG-I ligand 
in a sequence- and 5’-triphosphate-independent manner.70 In-
deed, short segments of reovirus, a segmented dsRNA virus, 
and short polyI:C can activate RIG-I-mediated signaling.71 
Infection by DNA viruses is also detected by RIG-I, through 
generation of dsRNA by polymerase III.72 RIG-I is coupled 
with signaling pathways that activate NF-κB, MAPKs, and 
IRFs, which result in production of type I IFNs with Inter-
feron beta promoter stimulator-1 (IPS-1) as an adaptor. IPS-
1 has an N-terminal CARD-like domain, sharing homology 
with RIG-I. The IPS-1 C-terminal domain contains a trans-
membrane segment that targets mitochondria.73-76 IPS-1-defi-
cient mice, exposed to RNA viruses, fail to activate NF-κB 
and IRF3, with the loss of type I IFN induction illustrating 
the critical role of IPS-1 in antiviral defense.77,78 However, 
in pDCs, IPS-1 deficiency did not affect type I IFN produc-
tion, indicating that TLRs contribute more than RLRs to vi-
ral recognition by pDCs. In other cell types, such as macro-
phages and fibroblasts, RLRs play central roles in viral Intrinsic and Extrinsic Regulation of Innate Immune Receptors
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molecule, TLR4 uses TRIF under limited conditions in a 
MyD88-independent manner. It has been questioned as to 
whether there is any regulatory mechanism for the prefer-
ential activation between MyD88- and TRIF-dependent 
signaling pathways in TLR4 signaling. A recent study sug-
gests that LPS structure, and its relationship with CD14, 
could provide the answer. LPS structure can be differentiat-
ed into ‘smooth LPS’ and ‘rough LPS’. Full-length O-
chains render the ‘smooth LPS’ structure, whereas the re-
duction of O-chains produces the ‘rough LPS’ structure. 
‘Rough LPS’ can bind to the TLR4/MD2 complex, while 
CD14 is required for ‘smooth LPS’ to bind to TLR4/MD2. 
When ‘rough LPS’ engages with a TLR4/MD2 complex in 
the absence of CD14, the complex initiates only MyD88-
dependent responses. On the other hand, either ‘smooth’ or 
‘rough LPS’, bound to TLR4, initiates both MyD88-depen-
dent and MyD88-independent responses, in a CD14-depen-
dent manner.95 TRIF recruits TRAF3 and TBK1 (TNF re-
ceptor-associated factor (TRAF) family member associated 
NF-κB activator binding kinase 1) in order to phosphory-
late IRF3. A knockout study, using TRIF-deficient mice, re-
vealed that production of type I IFNs, through TLR3 or 
TLR4, requires the presence of TRIF.94
MAL/TIRAP (MyD88-adapter-like protein/TIR domain-
containing adapter protein) is an adaptor molecule essential 
to the TLR2 and TLR4 signaling pathways. MAL/TIRAP 
acts as a bridge between MyD88 and TLR. MAL/TIRAP 
has an N-terminus binding domain that binds to phosphati-
dylinositol-4,5-bisphosphate; this process mediates the re-
cruitment of MAL/TIRAP to the plasma membrane and, in 
particular, to the microdomains that contain TLR4. MyD88 
does not bind directly to TLR4, but instead interacts with 
MAL/TIRAP in association with TLR4.90 TLR2 and TLR4 
signaling is impaired in cytokine production in MAL/TI-
RAP-deficient mice; however, TLR2 response is affected to 
a greater extent than TLR4 response.
TRAM (TRIF-related adaptor molecule) also known as 
TICAM2 plays an essential role in the MyD88-independent 
signaling pathway of TLR4. TRAM has a TIR domain, and 
acts as a bridge connecting TLR and TRIF, which allows for 
the activation of the TRIF dependent pathway in response 
to LPS.96 The activation of TRAM affects IRF3 and NF-κB 
activation as well. TRAM is regulated by myristoylation, 
which is required for the adaptor molecule to be localized 
within plasma membrane. Mutation of the myristoylation 
motif in TRAM abolishes the activation signal. Further-
more, protein kinase Cε (PKCε) phosphorylates TRAM. If 
NOD2.89 The NF-κB and MAP kinase pathways cooperate, 
leading to the transcription of the proinflammatory genes.
INTRACELLULAR SIGNALING 
COMPONENTS OF PRR
Adaptor molecules of PRRs
TLRs, RLRs and NLRs act through adaptor molecules to 
activate various kinases and transcription factors. Adaptor 
molecules are very important messengers that deliver sig-
nals from the receptors to protect the host from infection.
MyD88 (Myeloid differentiation primary response gene 
88) is one of the representative adaptor molecules in TLR 
signaling. ‘MyD’ refers to myeloid differentiation and ‘88’ 
stands for the number of the gene. MyD88 is a protein that 
is induced by terminal differentiation of M1D+ myeloid 
precursors and responses to IL-6.90 MyD88 is located in the 
cytosol near the cytosolic part of TLRs and delivers an acti-
vation signal that is initiated by receptor activation. MyD88 
is used by all TLR family members, except TLR3, to acti-
vate NF-κB. The structure of MyD88 is similar to that of 
TLR. MyD88 has an N-terminal death domain (DD), an in-
termediary domain (ID), and a C-terminal Toll-interleukin 
1 receptor (TIR) domain. The TIR domain of MyD88 can 
bind to the TIR domain of TLR directly or indirectly.91 The 
N-terminal death domain of MyD88 binds to the death do-
mains of other proteins, through homophilic DD-DD inter-
action, leading to the activation of NF-κB and JNK.92 In a 
past study, where MyD88 was knocked-out, treatment with 
ligands of TLR2, TLR5, TLR7, and TLR9 did not exhibit 
the proper immune responses.93 However, unlike other 
TLRs, TLR4 signals still exist in MyD88-deficient mice. 
This study led to the search for a MyD88-independent adap-
tor molecule, as it was suggested that TLR4 has another 
adaptor molecule, which was later discovered to be TRIF.
TRIF (TIR-domain containing adaptor protein inducing 
interferon-β) is another adaptor molecule associated with 
TLR signaling TRIF was found by database screening dur-
ing the search for a TIR domain containing protein. TRIF 
interacts with TLRs through TIR-TIR interaction. In con-
trast with MyD88, which is broadly used as an adaptor 
molecule in TLR signaling, TRIF is only involved in the 
signaling pathways of TLR3 and TLR4. TRIF is considered 
to be closely related to anti-viral signaling, since signals 
mediated by TRIF are linked to IRF activation and produc-
tion of IFN.94 While TLR3 only uses TRIF as its adaptor Eunshil Jeong and Joo Young Lee
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leased to translocate into nucleus. The IKK complex is a 
common factor for activating NF-κB, while the regulator of 
the IKK complex is different in each pathway.100
In addition to IKKs, MAPKs act as important kinases. 
The expression of IL-6, IL-8, IL-12p40, and MCP-1 is reg-
ulated by MAPK signaling.101 There are three groups of 
MAPKs in mammals: extracellular signal regulated kinase 
1/2 (ERK1/2), p38 proteins (α, β, γ, and δ), and c-Jun N-
terminal kinases (JNKs). The upstream MAPK kinases 
(MAPKKs or MEKs) are MEK1/2, MKK3/6, MKK4/7, 
and MEK5, respectively.102 ERK1/2, p38, and JNK are acti-
vated by various TLR ligands. Through MyD88, TRAF6 
activates a MAPK kinase kinase (MAPKKK) called trans-
forming growth factor-activated kinase (TAK1). Activated 
TAK1 can phosphorylate MKK3 and MKK6, the kinases 
upstream of p38 MAPKs and JNK.103 TAK1 can also acti-
vate the IKK complex. The activation of the IKK complex 
by TAK1 appears to be indirect, and the identity of the ki-
nase that is responsible for direct phosphorylation of the 
IKK complex remains unidentified.
TBK1 (TRAF family member-associated NF-κB activa-
tor (TANK) binding kinase-1) and IKKε (also known as 
IKKι) were initially implicated in IRF3 phosphorylation 
and activation, to produce type I IFN in the anti-viral re-
sponse. Overexpression of IKKε and TBK1 markedly acti-
vates NF-κB, as IKKε and TBK1 also regulate NF-κB, in 
addition to IRF3. IKKε was originally isolated as an LPS-
inducible protein in mouse macrophages and was shown to 
exhibit a similar sequence to canonical IKKs.104 TBK1 was 
identified as a protein kinase that interacts with TANK (also 
known as I-TRAF).105 TBK1 deficiency in mice results in 
embryonic lethality, around day 14.5, because of liver weak-
ness.106 Given that the lethality of TBK1-deficient mice is 
nullified when TNFR is absent, TBK1 might be involved in 
TNFR signaling to NF-κB, especially in the liver.107
IPS-1 interacts with receptor-interacting protein-1 (RIP-1), 
which was originally shown to be associated with the TNF 
receptor family of death receptors. RIP-1 is a death domain 
kinase, and is implicated in virus infection-induced type I 
IFN induction.108 IPS-1 interacts with RIP-1 via the non-
CARD region to facilitate NF-κB activation, rather than 
IRF3 activation. RIP-1 action is also facilitated by IPS-1 to 
activate NF-κB through activation of the IKK complex. 
RIP-1 is also involved in the TRIF pathway of TLR3 and 
TLR4.109 TRIF recruits RIP-1 upon TLR3 and TLR4 acti-
vation. In the absence of RIP-1, TLR3-induced NF-κB sig-
naling is abolished. 
phosphorylation is blocked, TRAM signals are impaired, 
which proves that PKCε is an essential component of the 
LPS-induced signaling pathway in macrophages.97 
SARM (sterile α- and armadillo-motif-containing protein)   
consists of a sterile α motif (SAM) and a TIR domain. SARM 
has been shown to be a negative regulator of NF-κB and 
IRF in TLR signaling.98 Knockdown of SARM expression 
in primary human peripheral-blood mononuclear cells led 
to increased poly I:C- and LPS-induced chemokine and cy-
tokine expression. Treatment of cells with LPS increased 
SARM protein levels, indicating negative feedback regula-
tion of the TLR4/TRIF pathway. Since it is unclear how 
SARM inhibits TRIF function, it will be important to clari-
fy this mechanism.
Among Toll-like receptors, endosomal TLRs require traf-
ficking proteins, which transport TLRs from ER to endo-
somes. UNC93B ER membrane protein carries TLR3, 
TLR7 and TLR9. In addition to UNC93B, Adaptor protein 
3 (AP-3) was also involved in TLR9 trafficking. AP-3 en-
hances the formation of the TLR9 complex with TRAF3 
and IRF7. In the absence of AP-3, CpG-A DNA-induced 
type I IFN production through the stimulation of TLR9 is 
impaired.96
Interferon beta promoter stimulator-1 (IPS-1) contains an 
N-terminal CARD domain which is homologous with the 
domain in RIG-I. IPS-1 is localized in mitochondria, and 
initiates a signaling process that activates IRF3 and NF-κB, 
via TBK1/IKKε and IKKα/IKKβ, respectively. IPS-1 binds 
to RIG-I through CARD-CARD interaction. IPS-1-defi-
cient mice fail to activate NF-κB and IRF3, with concomi-
tant loss of type I IFN and inflammatory cytokine induc-
tion, after infection.99
 
Main kinases in PRR signaling pathways
Phosphorylation is one of the typical mechanisms that acti-
vate signaling cascades. Signals from adaptor molecules ac-
tivate kinases, which can phosphorylate downstream mole-
cules to regulate transcriptional factors.
A multiprotein complex, termed the IKK (IκB kinase) 
complex, consists of two catalytic components, IKKα and 
IKKβ, and a regulatory component, NF-κB essential modifi-
er (NEMO, also known as IKKγ). IKKα and IKKβ are 
structurally similar, having a kinase domain, a leucine zipper 
domain, helix-loop-helix structures and a NEMO-binding 
domain (NBD). The IKK complex has a role in phosphory-
lating IκB. Phosphorylated IκB is degradated by ubiquitina-
tion. Then, NF-κB, which had been inhibited by IκB, is re-Intrinsic and Extrinsic Regulation of Innate Immune Receptors
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the promoter regions of its target genes, such as the IFN-
stimulated response element. Embryonic fibroblast cells 
from TBK1-deficient mice exhibit reduced IRF3 activation 
and IFN-β induction after stimulation with TLR3 and 
TLR4 ligands.113 While IKKε-deficient mice show no obvi-
ous changes with respect to IRF3 activation and IFN-β in-
duction, cells deficient in both TBK1 and IKKε exhibit a 
complete loss of IRF3 activation and IFN-β induction, indi-
cating a possible role of IKKε in IRF3 activation.107 Akt 
also participates in activation of IRF3 in TLR3 and -4 sig-
naling pathways as Akt knockdown by siRNA resulted in 
the diminishment of IRF3 phosphorylation and dimeriza-
tion.114 As TBK1 is able to enhance phosphorylation of Akt 
in response to TLR3 or -4 agonist, the interaction between 
TBK1 and Akt promotes IRF3 activation and IFNβ expres-
sion in TLR/TRIF-pathway. Notably, IRF3 activation by 
stimulation with TLR3 and TLR4 ligands is impaired in 
TRIF-deficient mice, but it is intact in MyD88-deficient 
mice, which suggests that IRF3 activation is controlled by 
the TRIF-dependent pathway. TBK1 and IKKε can also 
phosphorylate and activate IRF7, which is the member of 
the IRF family most closely related to IRF3.115 Whereas 
IRF3 is ubiquitously expressed and not inducible, IRF7 is 
expressed at low levels in most types of cells but is strongly 
induced in response to various stimuli.116 Therefore, IRF7 
might be involved in positive feedback regulation of type I 
IFN induction. 
INTRINSIC AND EXTRINSIC 
REGULATION OF PRR SIGNALING
Endogenous regulators
There exists a cellular device to prevent over- or unneces-
sary activation of PRRs. Several intracellular negative regu-
lators include MyD88s (the short form of MyD88), SOCS1, 
TOLLIP, A20, and CYLD (Fig. 2).
The most universal adaptor molecule in TLR signaling is 
MyD88, which is employed by TLR2, TLR4, TLR5, TLR7, 
TLR8 and TLR9. MyD88s lacks the intermediary domain 
that mediates DD interaction between IRAK4 and MyD88, 
which is present in wild-type MyD88. Although MyD88 is 
ubiquitously expressed, expression of MyD88s has only 
been detected in the spleen and, less strongly, in the brain. 
However, expression of MyD88s was upregulated in the 
human monocytic cell line (THP-1) following 16 hours of 
stimulation with LPS.117 In the presence of MyD88s, IRAK1 
The NLR proteins NOD1 and NOD2 interact with the 
serine-threonine kinase RICK (receptor-interacting protein 
(RIP)-like interacting caspase-like apoptosis regulatory pro-
tein kinase; also known as Ripk2 or RIP2), to induce NF-
κB and MAPK signaling. Direct or indirect ligand recogni-
tion by NOD1 and NOD2 induces recruitment of RICK 
through CARD-CARD interactions.110 This CARD-con-
taining serine-threonine kinase directly binds and promotes 
K63-type polyubiquitylation of the regulator IKKγ and ac-
tivation of the kinase TAK1,111 a prerequisite for activation 
of the IKK complex. These events result in the degradation 
of the NF-κB inhibitor IκBα and the subsequent transloca-
tion of NF-κB to the nucleus, where transcription of the 
NF-κB-dependent target gene occurs.
Major transcription factors of PRRs
The stimulation of TLRs, RLRs or NLRs delivers signals 
through adaptor molecules and kinases. Ultimately, tran-
scription factors, which trigger target gene transcription, are 
activated in the nucleus.
NF-κB is present in the cytoplasm, in an inactive form, 
captured by an inhibitor of NF-κB (IκB) proteins. Upon 
stimulation with various TLR ligands, IκBs are phosphory-
lated at serine residues by IKK complexes, which consist of 
IKKα and IKKβ protein kinases and a regulatory molecule, 
IKKγ/NEMO. Phosphorylation targets IκBs for ubiquitina-
tion and degradation, performed by the 26S proteasome, al-
lowing NF-κB to be released into the nucleus and to bind to a 
response element, which starts transcription of the target 
genes. 
AP-1 (Activator protein 1) has a dimeric basic region com-
posed of members of the Jun, Fos, activating transcription 
factor (ATF), and Maf subfamilies. AP-1 may bind to TPA-
response elements or cAMP-response elements. Among the 
AP-1 family proteins, c-Jun is thought to play a central role 
in inflammatory responses. AP-1 activation, in the TLR sig-
naling pathway, is mostly mediated by MAP kinases, such as 
JNK, p38 and ERK, through phosphorylation. Many TLR li-
gands activate MAP kinases with similar kinetics.112
TBK1 and IKKε have central roles in the induction of 
type I IFN through phosphorylation and activation of its 
transcription factors, IRF3 and IRF7. In a resting state, 
IRF3 is located in the cytoplasm in an inactive form; how-
ever, either TLR3 and TLR4 ligands or viral infection cause 
TBK1- and IKKε-mediated phosphorylation of the C-ter-
minal region of IRF3. This allows IRF3 to form a homodi-
mer and translocate into the nucleus, where it can bind to Eunshil Jeong and Joo Young Lee
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used the cytoplasmic tail of the IL-1R associated protein 
(residues 385-570) as bait to isolate a murine complemen-
tary DNA, which encodes a protein of 274 amino acids, in 
order to find a new component or IL-1R pathway. Further 
study showed that Tollip was also able to interact with sev-
eral members of the TIR superfamily, including TLR2 and 
TLR4.121 Overexpression of Tollip has been shown to result 
in inhibition of TLR2- and TLR4-mediated NF-κB activa-
tion. Tollip interacts with IRAK1, and the level of IRAK1 
autophosphorylation is reduced in the presence of Tollip. 
IRAK1 causes phosphorylation of Tollip upon TLR stimu-
lation. Although the physiological importance of this is un-
clear, it is possible that phosphorylation of Tollip facilitates 
the ubiquitinylation of IRAK1 and its subsequent degrada-
tion. In addition, Tollip expression is elevated in intestinal 
epithelial cells that are hypo-responsive to TLR2 ligands. 
Therefore, phosphorylation and dephosphorylation of Toll-
ip and IRAK, in the TLR signaling pathway, may be a switch 
for TLR4- and TLR2-mediated responses.
A20 was initially identified as a TNF-induced zinc-finger 
protein that suppresses TNF-mediated NF-κB activation.122 
was still recruited, through a death-domain interaction with 
MyD88s, but was no longer phosphorylated.118 The pres-
ence of MyD88s prevents IRAK4 from phosphorylating 
IRAK1, since D88s cannot associate with IRAK4. This in-
dicates that MyD88s might be involved in a negative-feed-
back regulatory mechanism that controls excessive TLR 
activation.119
Macrophages from SOCS1-deficient mice exhibited en-
hanced phosphorylation of STAT1, IκBα, p38, and JNK, 
and produced high levels of nitric oxide and pro-inflamma-
tory cytokines, in response to the presence of TLR4 and 
TLR9 ligands, LPS and CpG DNA, respectively.120 SOCS1-
deficient mice die within three weeks of birth from multi-
organ inflammation and high susceptibility to sepsis. Fur-
thermore, LPS and CpG DNA induced SOCS1 expression 
in macrophages, which indicates that SOCS1 is a non-re-
dundant negative regulator of TLR signaling, and may par-
ticipate in the termination and resolution processes of in-
flammation.
Tollip (Toll-interacting protein) was originally identified 
through a yeast-two-hybrid screening process. The process 
Fig. 2. Endogenous and exogenous regulators of TLR activation. Endogenous negative regulators of TLRs are revealed. The short form of MyD88 (sMyD88) sub-
stitutes MyD88 but cannot send signals downstream. Tollip interacts with IRAK to decrease phosphorylation. A20 deubiquitylates TRAF6. SOCS1 regulates phos-
phoryltation of IκBα, p38, and JNK. Exogenous TLR regulators have been identified. Small molecules such as surforaphane, cinnamaldehyde, and curcumin 
block oligomerization of the receptor, whereas resveratrol, EGCG, and certain flavonoids such as lutelolin, quercetin, chrysin, and eriodictyol have the ability to 
decrease kinase activity of TBK1. In addition, ligand binding to the receptor complex can be another target for regulation of the TLR signaling pathway.
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However, there remain unrevealed mechanisms for well-
known anti-inflammatory agents. This leads us to search for 
new therapeutic targets for the treatment of inflammatory 
diseases and immune disorders. 
Receptor oligomerization is an initial step of TLR signal-
ing, which triggers the association of intracellular domains 
to provide a platform for the recruitment of downstream 
molecules. When dimerization is blocked, the signal cannot 
be delivered to the adaptor molecules and downstream sig-
naling cascades. Recently, the suppression of TLR dimer-
ization has been suggested as the inhibitory target for small 
molecules such as curcumin, cinnamaldehyde, and sulfora-
phane, which have been reported to have anti-inflammatory 
effects (Fig. 2).126,127 Thiol-modifying activity appears to be 
related to the action of these phytochemicals since a supple-
ment of thiol-donors reversed the inhibitory effects of the 
phytochemicals on TLR4 activation. Indeed, the study us-
ing LC-MS/MS analysis has revealed that sulforaphane 
binds directly to cysteine residues in the TLR4 extracellular 
domain and inhibits TLR4-TLR4 interaction. These results 
suggest that receptor clustering, especially the dimerization 
step, could be a novel target for TLR regulators, and that the 
modification of cysteine residues could be a promising 
strategy for modulating TLR activation.127
The representative kinase found in TRIF-dependent TLR 
signaling is TBK1. TBK1 acts as a critical kinase for IRF3 
activation and type I IFNs production by phosphorylating 
IRF3. Resveratol and its structural analog stilbene specifi-
cally inhibit TRIF signaling in the TLR3 and TLR4 path-
way by targeting TBK1. Resveratol directly blocks TBK1 
kinase activity, as demonstrated by an in vitro kinase assay 
(Fig. 2).128 Certain flavonoids such as EGCG, luteolin, 
quercetin, chrysin, and eriodictyol also inhibit TBK1 kinase 
activity, resulting in a decrease in IRF3 activation and target 
gene expression, while naringenin and hesperetin had no 
such effect (Fig. 2). This proves that kinases, especially 
TBK1, can be a regulatory target in TLR signaling, and 
provide a potential base for developing an inflammation in-
hibitor.129,130
In case of TLR4, MD2 is the essential partner in receptor 
cluster forming two TLR4-MD2 complexes upon engage-
ment of LPS. Understanding the structure of MD2 and the 
interaction between MD2 and LPS can suggest a therapeu-
tic strategy for regulating TLR4 activation. A free cysteine 
residue at the 133 position within a binding pocket of MD2 
has been suggested as an important site for modulating the 
interaction between MD2 and LPS. Binding of MD2 Cys133 
A20 expression is rapidly induced by both TLR4 ligands, 
LPS and TNF, and is expressed in many cell types, which 
suggests that it is involved in regulating TLR function. Mac-
rophages from A20-deficient mice produced elevated levels 
of pro-inflammatory cytokines when stimulated with the 
TLR2 ligands (peptidoglycan and lipoteichoic acid), the 
TLR3 ligand (poly I:C), and the TLR9 ligand (CpG DNA).123 
A20 is important in preventing the host from developing 
endotoxic shock; however, A20 deficiency does not play an 
important part in LPS tolerance. A20 is a cysteine protease 
de-ubiquitylating enzyme that blocks TLR mediated signal-
ing by deubiquitylating TRAF6. A20 is a negative regulator 
that can control both MyD88-dependent and MyD88-inde-
pendent TLR-signaling pathways.
The tumor suppressor CYLD (cylindromatosis) is a neg-
ative regulator of the RIG-I-mediated innate antiviral re-
sponse.124 Ectopic expression of CYLD inhibits both the 
IRF3 signaling pathway and IFN production triggered by 
RIG-I; conversely, CYLD knockdown enhances the RIG-I-
induced IFN production. CYLD is closely related, in its 
function, to a deubiquitinating enzyme that removes Lys 
63-linked polyubiquitin chains, which suggests a functional 
association between the two molecules. CYLD removes 
polyubiquitin chains from RIG-I as well as TBK1, which is 
the kinase that phosphorylates IRF3, inhibiting the IRF3 
signaling pathway. Furthermore, CYLD protein level is re-
duced by tumor necrosis factor or viral infection, concomi-
tant with enhanced IFN production. 
Poly(ADP-ribose) polymerases (PARPs), which regulate 
cell survival, cell death, and other biological functions, con-
sist of at least 17 members. Among them, PARP-13 (ZAP) is 
known to be involved in IFN production against viral infec-
tion. The shorter form of PARP-13 (ZAPS) is an especially 
strong stimulator of the RIG-I-signaling pathway, as it re-
sponds to 5’-triphosphate-modified RNA (3pRNA). ZAPS 
promotes the activation of IRF3 and NF-κB through its asso-
ciation with RIG-I. The production of not only IFN but also 
of other inflammatory cytokines such as IL-6, TNF-α and 
CXCL10 is regulated in a ZAPS-dependent manner.125
Regulation of PRR activation by exogenous substances
Since the activation of PRRs is closely associated with the 
risk of chronic inflammatory diseases and immune disor-
ders, the identification of therapeutic target points in PRR 
signaling could provide critical information for the preven-
tion and treatment of these diseases. IKKβ and NF-κB have 
long been popular targets for anti-inflammation studies. Eunshil Jeong and Joo Young Lee
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tion and danger signals, and causes severe diseases. There-
fore, discovery of new receptors and investigation into their 
downstream signal activation mechanisms, are essential in 
order to understand how to efficiently regulate the immune 
system and, eventually, to advance the quality of human 
life. As the effort to develop new therapeutic agents modu-
lating PRRs is being extensively pursued,137 identification 
of novel regulatory targets provides an important informa-
tion on constructing beneficial therapeutic strategies. 
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